Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study
C. Dvorak, P. Satwani, Elliot Stieglitz, et al.. (2018). Pediatric Blood & Cancer. Cited 31 times. https://doi.org/10.1002/pbc.27034
Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia
Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children's Oncology Group.